Travere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS Transcript

SA Transcripts159.28K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Travere Therapeutics, Inc. (TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS April 13, 2026 6:45 PM EDT Company Participants Nivi Nehra - Vice President of Corporate Communications & Investor RelationsEric Dube - President, CEO & DirectorJula Inrig - Chief Medical OfficerPeter Heerma - Chief Commercial OfficerChris Cline - Chief Financial OfficerWilliam Rote - Chief Research Officer Conference Call Participants Joseph Schwartz - Leerink Partners LLC, Research DivisionPriyanka Grover - JPMorgan Chase & Co, Research DivisionVamil Divan - Guggenheim Securities, LLC, Research DivisionLaura Chico - Wedbush Securities Inc., Research DivisionTyler Van Buren - TD Cowen, Research DivisionPrakhar Agrawal - Cantor Fitzgerald & Co., Research DivisionSadia Rahman - Wells Fargo Securities, LLC, Research DivisionMaurice Raycroft - Jefferies LLC, Research DivisionYigal Nochomovitz - Citigroup Inc., Research DivisionJason Zemansky - BofA Securities, Research DivisionAlexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Good afternoon, and welcome to the Travere Therapeutics Business Update Conference Call. Today's call is being recorded. At this time, I would like to turn the conference call over to Nivi Nehra, Vice President, Corporate Communications and Investor Relations. Please go ahead, Nivi. Nivi NehraVice President of Corporate Communications & Investor Relations Thank you, operator. Good evening, and thank you all for joining us today on such short notice. Earlier today, we announced the FDA has approved FILSPARI in FSGS. A copy of the press release, along with the slides that we'll be referencing on today's call, can be found on our corporate website. Today's call will be led by our President and Chief Executive Officer, Dr. Eric Dube. Eric will be joined in the prepared remarks by Dr. Jula Inrig, our Chief Medical Officer; and Peter Heerma, our Chief Commercial Officer. Dr. Bill Rote, our Chief Research Officer; and Chris Cline, our Chief Financial Officer, will join us for the Q&A.